Galmed Pharmaceuticals Ltd
NASDAQ:GLMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Galmed Pharmaceuticals Ltd
Net Income (Common)
Galmed Pharmaceuticals Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Galmed Pharmaceuticals Ltd
NASDAQ:GLMD
|
Net Income (Common)
-$10.3m
|
CAGR 3-Years
17%
|
CAGR 5-Years
19%
|
CAGR 10-Years
0%
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Net Income (Common)
$20.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Net Income (Common)
$1.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Net Income (Common)
-$153.5m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Net Income (Common)
-$11.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Net Income (Common)
-$26.1m
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-2%
|
|
Galmed Pharmaceuticals Ltd
Glance View
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
See Also
What is Galmed Pharmaceuticals Ltd's Net Income (Common)?
Net Income (Common)
-10.3m
USD
Based on the financial report for Dec 31, 2025, Galmed Pharmaceuticals Ltd's Net Income (Common) amounts to -10.3m USD.
What is Galmed Pharmaceuticals Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
0%
Over the last year, the Net Income (Common) growth was -37%. The average annual Net Income (Common) growth rates for Galmed Pharmaceuticals Ltd have been 17% over the past three years , 19% over the past five years .
